Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT03700606
Other study ID # HFNC
Secondary ID
Status Completed
Phase N/A
First received
Last updated
Start date March 15, 2019
Est. completion date February 14, 2022

Study information

Verified date May 2022
Source Sharp HealthCare
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

To measure changes in physiologic parameters in extremely low birthweight (ELBW) infants on high-flow nasal cannula compared to nasal continuous positive airway pressure (nCPAP).


Description:

After informed consent is obtained, eligible infants who are stable on nCPAP therapy of 5-7 cm H20 achieved with a ventilator, an underwater "bubble" system, or a variable-flow device will be enrolled. All subjects will have physiologic data and electrical impedance tomography collected at: 1. Baseline nCPAP for 15 minutes 2. Upon transition to high flow nasal cannula at 8 LPM for 6 hours. Data collection is obtained after infant is calm for 15 minutes at the beginning and end of this 6 hour period 3. Then upon return to baseline NCPAP for a final 15 minutes of data collection.


Recruitment information / eligibility

Status Completed
Enrollment 80
Est. completion date February 14, 2022
Est. primary completion date December 20, 2021
Accepts healthy volunteers No
Gender All
Age group 23 Weeks to 29 Weeks
Eligibility Inclusion Criteria: - 23 to 28+6 weeks gestational age at birth - Corrected gestational age less than or equal to 30 weeks - Over 72 hours of life - Stable on Nasal CPAP of 5-7cm H20 - Hemodynamically stable - Tolerating routine handling - Nares size appropriate for Fisher & Paykel Optiflow Jr 2 HFNC size XS or small - Successfully extubated for 12 hours after administration of surfactant - Caffeine Citrate at a maintenance dose of 5 to 10 mg /kg - Transcutaneous monitoring in place - Stable blood gas (pH>/= 7.25 and PaCO2 <60 mmHg torr) Exclusion Criteria: - Prior pneumothorax or evidence of pulmonary interstitial emphysema. - Prior or current pulmonary hemorrhage - Congenital airway malformations - Major cardiopulmonary malformations - Congenital Diaphragmatic hernia or untreated bowel obstruction - Poor respiratory drive unresponsive to CPAP therapy - Requirement of a nCPAP of >8 cmH20 or FiO2 > 0.3 to maintain oxygen saturations between 90-95 percent. - Receiving positive pressure breaths or SIPAP on prongs - Conflicting clinical trial - Clinically unstable per physician discretion

Study Design


Related Conditions & MeSH terms


Intervention

Procedure:
High flow nasal cannula
8 liters per minute of blended oxygen through Fisher Paykel Optiflow Jr 2 nasal prongs.
Nasal CPAP
Nasal continuous positive airway pressure of 5-7 cm/H20 delivered using Ventilator or bubble cpap device through short nasal prongs or a nasal face mask.

Locations

Country Name City State
United States Sharp Mary Birch Hospital for Women & Newborns San Diego California

Sponsors (1)

Lead Sponsor Collaborator
Sharp HealthCare

Country where clinical trial is conducted

United States, 

Outcome

Type Measure Description Time frame Safety issue
Primary % Unventilated Lung Atelectasis will be calculated using the percentage of the lung fields that are not engaged in tidal volume.(VT) Through study completion, an average of 30 days
Secondary Geometric Center of Ventilation (CoV) numeric value that describes the geographic point within the thorax that represents the statistical center of VT Through study completion, an average of 30 days
Secondary End-expiratory lung volume % of total VT within 8 lung regions, relative change in uncalibrated aeration Through study completion, an average of 30 days
See also
  Status Clinical Trial Phase
Recruiting NCT04016246 - Respiratory Effect of the LISA Method With Sedation by Propofol Versus Absence of Sedation. Phase 3
Enrolling by invitation NCT04118400 - Ventilator Weaning Outcome Between NIV-NAVA and Nasal CPAP (or IMV ) Modes in Premature Neonates
Completed NCT01941745 - Efficacy of Recombinant Human Clara Cell 10 Protein (rhCC10) Administered to Premature Neonates With Respiratory Distress Syndrome Phase 2
Not yet recruiting NCT04019106 - Budesonide With Intratracheal Surfactants in Extremely Preterm Infants Phase 1/Phase 2
Not yet recruiting NCT04862377 - Intratracheal Budesonide With Surfactant to Prevent Bronchopulmmonary Dysplasia. Phase 3
Not yet recruiting NCT05791331 - REspiratory MEchanics for Delivering Individualised Exogenous Surfactant N/A
Completed NCT04086095 - Feasibility Study - Neofact N/A
Not yet recruiting NCT05609877 - The NONA-LISA Trial N/A
Recruiting NCT04326270 - Crossover Comparison of Tidal Volume Delivery During Nasal Intermittent Positive Pressure Ventilation in Preterm Infants: Infant Cannula vs. Nasal Continuous Positive Airway Pressure Prongs N/A
Active, not recruiting NCT03969992 - A Dose-Ranging Study to Determine the Efficacy, Safety and Tolerability of AeroFact Phase 2
Recruiting NCT04359134 - Combined Lung Ultrasounds and Transthoracic Electrical Bioimpedance in Preterm Infants With Respiratory Distress.
Not yet recruiting NCT06229821 - Safety and Efficacy of Intrapulmonary Percussive Ventilation in Preterm Infants N/A
Recruiting NCT05446389 - PAL to Improve Oral Feeding for Infants With Chronic Lung Disease N/A
Withdrawn NCT04914715 - nHFOV Versus Invasive Conventional Ventilation for Preterm Neonates With Respiratory Distress Syndrome N/A
Recruiting NCT03825835 - 30% or 60% Oxygen at Birth to Improve Neurodevelopmental Outcomes in Very Low Birthweight Infants N/A
Recruiting NCT03562182 - Effect of Steroid Administration on Maternal Blood Levels of hLPCAT1 mRNA
Completed NCT05031650 - Open Lung Strategy During Non-Invasive Respiratory Support of Very Preterm Infants in the Delivery Room N/A
Completed NCT03306524 - The Role of Circuit Flow During Mechanical Ventilation of Neonates N/A
Completed NCT01473264 - Safety, Pk and Anti-inflammatory Effects of CC10 Protein in Premature Infants With Respiratory Distress Syndrome (RDS) Phase 1/Phase 2
Completed NCT03548324 - Enteral Nutrition Tolerance And REspiratory Support (ENTARES) N/A